Alnylam Unveils 'Alnylam 2030' Strategy Targeting 25% CAGR Through 2030
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 22h ago
0mins
Source: NASDAQ.COM
- Strategic Vision: Alnylam has unveiled its five-year 'Alnylam 2030' strategy aimed at achieving leadership in ATTR amyloidosis through sustainable innovation, thereby driving long-term growth and ensuring financial discipline.
- Revenue Growth Target: The company anticipates a compound annual growth rate (CAGR) exceeding 25% by 2030, while targeting a non-GAAP operating margin of around 30% to ensure sustained profitable growth.
- Product Revenue Performance: For Q4 2025, global net product revenues for AMVUTTRA and ONPATTRO were approximately $827 million and $32 million, respectively, together reflecting a robust 151% year-over-year growth, indicating strong market demand.
- Future Product Pipeline: Alnylam plans to launch its next-generation drug nucresiran by 2028 and aims to achieve revenue leadership in the TTR market by 2030, further expanding its clinical pipeline to over 40 programs, showcasing its innovation capabilities and market potential.
Analyst Views on ALNY
Wall Street analysts forecast ALNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALNY is 497.68 USD with a low forecast of 370.00 USD and a high forecast of 570.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
21 Analyst Rating
17 Buy
4 Hold
0 Sell
Strong Buy
Current: 398.290
Low
370.00
Averages
497.68
High
570.00
Current: 398.290
Low
370.00
Averages
497.68
High
570.00
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
